SUVN-D4010

DRUG2 trials

Sponsors

Suven Life Sciences Limited

Conditions

Cognitive DisorderCognitive Disorders

Phase 1

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

CompletedNCT02575482

Suven Life Sciences LimitedCognitive Disorders

Start: 2015-07-31End: 2016-06-30Updated: 2016-06-06

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects

CompletedNCT03031574

Suven Life Sciences LimitedCognitive Disorder

Start: 2017-01-23End: 2017-09-07Updated: 2017-09-25

Related Papers

First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT<sub>4</sub> Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.

2021-03-315 citations